OR WAIT null SECS
December 17, 2024
Video
Clark reviews open-label extension data from the phase 2b SEQUOIA study of fazirsiran for AATD liver disease.
November 27, 2024
Fromme describes the importance of risk stratification in AATD and explains the potential utility of noninvasive fibrosis measures for predicting outcomes.
November 26, 2024
Strnad reviews findings from a proteomic analysis about AATD-associated liver disease and how they may aid future disease monitoring and drug development.
November 18, 2024
Teckman explains the value of a new predictive algorithm model for determining future risk of portal hypertension, cirrhosis, and liver transplant in AATD.
October 16, 2024
Article
Proof-of-mechanism data from the phase 1b/2a study of WVE-006 represent the first-ever clinical demonstration of RNA editing in humans.
September 25, 2024
Findings from the prospective cohort study suggest the value of serum Z polymer levels as a non-invasive disease-specific biomarker in patients with homozygous ZZ AATD liver disease.
September 05, 2024
The Delphi survey collected opinions from members of the European Alpha-1 Research Collaboration to guide the diagnosis, treatment, and management of severe AATD.
August 22, 2024
Strnad explains how although moderate alcohol consumption is likely tolerable in most individuals with AATD, careful monitoring of liver-related parameters is still important.
August 17, 2024
Moderate alcohol consumption did not significantly impact liver-related parameters in patients with the Pi*MZ and Pi*ZZ genotypes of alpha-1 antitrypsin deficiency.
August 16, 2024
Strnad explains the need for noninvasive biomarkers in AATD liver disease and early research about circulating Z-polymer’s potential association with clinically relevant adverse outcomes.